Despite the increasing awareness of the molecular mechanisms of IDH mutations on cancer metabolism and transformation, it remains elusive as to how metabolic deficient cancers, such as IDH1-mutated glioma, acquire an aggressive phenotype during oncogenic transformation. This evidence concerns the gene IDH2 and central nervous system cancer.